High-dose, frequently administered interferon beta therapy for relapsing–remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study
- 15 July 2004
- journal article
- clinical trial
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 222 (1-2) , 13-19
- https://doi.org/10.1016/j.jns.2004.03.023
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)The Lancet, 2002
- Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosisThe Lancet, 1998
- Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosisNeurology, 1998
- Characterization of MRI response to treatment with interferon beta-1b: Contrast-enhancing MRI lesion frequency as a primary outcome measureNeurology, 1997
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Immunoregulatory effects of interferon-β and interacting cytokines on human vascular endothelial cells implications for multiple sclerosis and other autoimmune diseasesJournal of Neuroimmunology, 1996
- Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosisAnnals of Neurology, 1996
- The effect of interferon‐β on blood—brain barrier disruptions demonstrated by constrast‐enhanced magnetic resonance imaging in relapsing—remitting multiple sclerosisAnnals of Neurology, 1995
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993
- Rating neurologic impairment in multiple sclerosisNeurology, 1983